Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

VIMRx acquires worldwide rights to wound-healing agent

May 21, 1997

Ointment formulation of BioCryst's BCX-34 enters phase II for psoriasis

May 20, 1997

Safety, pharmacological, phase I and early phase II results for SM-10902

May 20, 1997

CytoMed initiates phase II trials of CMI-392

May 9, 1997

Dermik introduces combination acne therapy in South Africa

May 9, 1997

FDA advisory panel denies approval for Genzyme's Sepracoat

May 8, 1997

Abbott discovers potent topical immunosuppressant with minimal systemic effects

April 30, 1997

Positive phase III results from Hyal's actinic keratosis trial

April 28, 1997

Gliatech's ADCON-L to recieve expedited review by FDA

April 24, 1997

LifeCell reports clinical data on AlloDerm

April 23, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...